AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data

AtaiBeckley Inc. (NASDAQ:ATAI) on Thursday shared topline results from an exploratory Phase 2a trial of EMP-01, an oral R-MDMA treatment for Social Anxiety Disorder.The encouraging data highlights a favorable safety profile and significant patient improvement, which may be contributing to the stock’s upward movement from an exploratory Phase.Social Anxiety DataIn the trial, 49% of patients receiving EMP-01 were rated as “very much improved” or “much improved,” compared to only 15% in the placebo group, indi ...